Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9–14 Years in the EU
- 207 Downloads
A two-dose vaccination schedule for the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is approved for the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types in girls aged 9–14 years in countries in the EU and elsewhere. In this patient population, the two-dose schedule elicited a high immunogenic response that matched that of the three-dose schedule in women aged 15–25 years and, therefore, was inferred to provide clinical protection against oncogenic HPV cervical infection and, consequently, against precancerous lesions and cervical cancer.
KeywordsCervical Cancer Anogenital Wart ELISA Unit Premalignant Cervical Lesion PBNA
The preparation of this review was not supported by any external funding. The author has requested that GSK reviews this article in an advisory capacity as part of the peer review process. GSK’s review has been limited to the data related to GSK’s vaccine; the author retains sole responsibility for the scope and content of the article; changes resulting from comments received from GSK were made by the author on the basis of scientific and editorial merit.
- 2.Asiaf A, Ahmad ST, Mohammad SO, et al. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur J Cancer Prev. 2013 (Epub ahead of print).Google Scholar
- 4.Alemany L, de Sanjosé S, Tous S, et al. Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. Int J Cancer. 2013. doi: 10.1002/ijc.28636.
- 8.Cervarix suspension for injection. Human papillomavirus vaccine [types 16,18] (recombinant, adjuvanted, adsorbed): summary of product characteristics. London: European Medicines Agency; 2014.Google Scholar
- 9.Gardasil, suspension for injection. Human papillomavirus vaccine [types 6,11,16,18] (recombinant, adsorbed): summary of product characteristics. London: European Medicines Agency; 2013.Google Scholar
- 13.Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2013: United States. MMWR Morb Mortal Wkly Rep. 2013;62(29):591–5.Google Scholar
- 16.GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, Colares de Borba P, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374(9706):1975–85.PubMedCrossRefGoogle Scholar
- 17.Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women [published erratum appears in Lancet 2010; 376: 1054]. Lancet. 2009;374(9686):301–14.PubMedCrossRefGoogle Scholar
- 20.Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. Hum Vaccin. 2011;7(12):1359–73.PubMedCentralPubMedCrossRefGoogle Scholar
- 21.Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a phase III randomized study of healthy women aged 18–45 years. Hum Vaccin. 2011;7(12):1343–58.PubMedCentralPubMedCrossRefGoogle Scholar
- 28.Puthanakit T, Schwarz T, Esposito S, et al. Immune responses to a 2-dose schedule of the HPV-16/18 AS04-adjuvanted vaccine in girls (9–14) versus 3 doses in women (15–25): a randomised trial [abstract no. IW-1-5]. EUROGIN 2013 International Multidisciplinary Congress, Florence; 2013.Google Scholar
- 30.Romanowski B, Schwarz TF, Ferguson LM, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother. 2014 (Epub ahead of print).Google Scholar
- 31.Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100–10.PubMedCrossRefGoogle Scholar
- 35.Angelo M-G, David M-P, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.3554.
- 36.Cervical cancer, human papillomavirus (HPV), and HPV vaccines: key points for policy-makers and health professionals. Geneva: WHO Document Production Services; 2008.Google Scholar